China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor, announced a strategic partnership with compatriot firm China Biotech Services Holdings Ltd. The collaboration aims to integrate medical services, innovation, and technology to enhance offerings in health testing, medical assistance, and advanced cancer therapies.
Partnership Details
- Cancer Testing: Ping An Good Doctor will collaborate with China Biotech Services’ Hong Kong testing center to provide integrated cancer testing services. The center will offer bilingual reports and consultation appointments with local experts.
- Medical Assistance: Subsidiaries of China Biotech Services will assist Ping An Good Doctor users with overseas medical services in Japan, including remote consultations, secondary diagnoses, high-end physical exams, postoperative care, and follow-up testing.
- BNCT Therapy: China Biotech Services will leverage its medical resources to support Ping An Good Doctor’s customers with Boron Neutron Capture Therapy (BNCT). The therapy, approved in Japan for head and neck cancers, uses a non-radioactive boron isotope to target cancer cells. BNCT offers advantages such as short treatment duration, high efficiency, and broad indications.
Clinical and Regulatory Background
BNCT has completed Phase I/II trials in head and neck tumors, glioma, melanoma, and liver cancer. Approved in Japan and covered by medical insurance, it is a promising alternative to traditional cancer treatments.-Fineline Info & Tech
